By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
A unique technology platform developed by Breath Diagnostics to quantitatively analyze organic compounds in a single breath to detect lung cancer and other diseases.1
Our highly portable system will be readily available to patients through medical providers.1
In contrast to a Low-Dose CT Scan, OneBreath is a quicker and easier way of lung cancer diagnosis. We are currently enrolling patients for our 2nd generation system Pilot Study.
Breath Collection
Patients provide one complete breath via a unique collection system in less than 30 seconds.
Breath Processing and Analysis
In a simple automated process, the OneBreath™ micro-reactor captures the organic compounds contained in the breath. Once captured, the samples is analyzed in our laboratories.
Get Results
Results will be available within 3-4 business days.
Why OneBreath™?
OneBreath™ provides a safe, convenient, and inexpensive way to identify lung cancer in at risk patients, before they know they have a problem.1
Accurate Results
OneBreath™ detects lung cancer with fewer false positives and higher specificity than a low-dose CT scan.
Accessible
The OneBreath™ system increases access to potentially life-saving lung cancer screenings by being portable enough for use in a physician's office or local pharmacy.
Affordable
The OneBreath™ technology platform demonstrates a lower false positive rate versus CT scans, reducing the number of unnecessary follow-up diagnostic procedures.
Easy to Use
The simplicity of the OneBreath™ system provides the potential to enhance screening compliance due to the fact that only a single breath is required.
A feasibility study on exhaled breath analysis using UV spectroscopy to detect COVID-19
"Our feasibility study demonstrates that a single UV absorbance measurement of a concentrated breath sample has promise as a screening approach to detect increased levels of carbonyl compounds, which may be indicative of a disease state such as COVID-19.
Research
January 10, 2023
Identification of a marker of infection in the breath using a porcine pneumonia model
Pneumonia, both in the community and the hospital setting, represents a significant cause of morbidity and mortality in the cardiothoracic patient population. Diagnosis of pneumonia can be masked by other disease processes and is often diagnosed after the patient is already experiencing the disease. A noninvasive, sensitive test for pneumonia could decrease hospitalizations and length of stay for patients. We have developed a porcine model of pneumonia and evaluated the exhaled breath of infected pigs for biomarkers of infection.